Moreover, both Rabaptin-5 and HD-PTP are known tumour suppressors (Gingras et al., 2017; Thomas and Strutt, 2014), and changes in their protein expression lead to prolonged receptor activity. The gene discussed is PTPN23; the disease is neoplasm.